Living with a bleeding disorder can be challenging. Hemophilia Treatment Centers (HTCs) play a critical role in caring for patients reducing hospitalizations, mortality, and other complications.1 As federal funding has decreased, HTCs use 340B programs to make up for limited funding.
Many HTCs use a combination of contracted and in-house pharmacy services to manage their 340B programs. Contract pharmacy arrangements can help HTCs with existing or new 340B programs maintain regulatory compliance, maximize cost savings, and promote patient engagement.
Jeff Johnson is a patient with hemophilia who is a BioMatrix Regional Care Coordinator serving an HTC 340B program in the Northwest. “My role is to enhance the efforts of the HTC and support the patients served through the 340B program. The relationships I form are based on trust and shared experience as a fellow community member,” Johnson said.
“Coordinating every step with HTC and our pharmacy team, I help patients effectively navigate common coverage or insurance challenges, access programs reducing financial burden, reinforce the importance of care standards, and coordinate accurate and timely refill support,” he said. “I feel our efforts help improve adherence, continuity, and overall connectivity with the comprehensive care team.”
Read more about 340B contract pharmacy partnerships in our article published in Pharmacy Times.
Stay informed on the latest trends in healthcare and specialty pharmacy.
Sign up for our monthly e-newsletter, BioMatrix Abstract.
We value your privacy. Review our Privacy Policy here.
References
Hemophilia treatment centers (HTCs). CDC. Updated July 17, 2020. Accessed June 22, 202 https://www.cdc.gov/ncbddd/hemophilia/htc.html[RP1]
